Catharine Scott-Moncrieff, DVM, PhD, explains when she prescribes insulin versus SGLT2 inhibitors, how to monitor for ketosis, and which factors most influence diabetic remission in cats.

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. As far as SGLT2 inhibitors for first-line therapy in ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

Affordability of SGLT2i may contribute to the low prescription rate in CKD. Although clinical trials have demonstrated favorable cardiovascular and kidney effects from use of sodium-glucose ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we ...

Sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure (HF) related to adult congenital heart disease (ACHD) and associated with reduced ...

Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...